STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 CALIFORNIA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

			Number of Be	eneficiaries				1	Number of Be	nefit Months		
Beneficiary	'					Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	5,642,718	74,413	463,123	2,936,193	2,163,000	5,989	37,644,944	694,514	4,873,512	20,604,975	11,412,232	59,711
Age												
5 and younger	974,623	1	15,534	4	959,084	0	4,524,994	12	141,392	6	4,383,584	0
6-14	772,516	0	41,025	188	731,303	0	4,618,088	0	439,192	511	4,178,385	0
15-20	898,823	0	34,287	412,320	452,188	28	6,074,316	0	365,986	2,947,910	2,760,179	241
21-44	2,458,046	6	139,228	2,296,802	20,338	1,672	17,829,163	22	1,476,810	16,246,544	89,724	16,063
45-64	455,109	19	224,359	226,445	60	4,226	3,807,105	107	2,355,959	1,408,083	248	42,708
65-74	52,866	44,749	7,708	346	0	63	507,888	420,786	84,808	1,595	0	699
75-84	23,622	22,799	779	42	2	0	226,339	218,370	7,742	212	15	0
85 and older	7,097	6,839	203	46	9	0	57,024	55,217	1,623	114	70	0
Unknown	16	0	0	0	16	0	27	0	0	0	27	0
Gender												
Female	3,831,525	46,365	226,531	2,421,357	1,131,286	5,986	26,473,161	435,733	2,411,896	17,513,895	6,051,962	59,675
Male	1,811,185	28,048	236,592	514,836	1,031,706	3	11,171,750	258,781	2,461,616	3,091,080	5,360,237	36
Unknown	8	0	0	0	8	0	33	0	0	0	33	0
Race												
White	1,267,500	14,251	175,345	625,619	450,947	1,338	9,642,029	126,718	1,842,675	4,449,748	3,209,874	13,014
African American	468,867	2,648	84,177	208,487	173,181	374	3,149,575	22,096	881,325	1,289,861	952,662	3,631
Other/unknown	3,906,351	57,514	203,601	2,102,087	1,538,872	4,277	24,853,340	545,700	2,149,512	14,865,366	7,249,696	43,066
Use of Nursing Facilities ^c												
Entire year	6,886	1,357	5,460	29	36	4	74,877	14,335	59,907	191	402	42
Part year	8,832	1,521	6,903	294	82	32	87,668	14,920	69,812	1,986	621	329
None	5,627,000	71,535	450,760	2,935,870	2,162,882	5,953	37,482,399	665,259	4,743,793	20,602,798	11,411,209	59,340
Maintenance Assistance Status												
Cash	1,842,658	9,475	400,086	509,502	923,595	0	12,434,242	102,246	4,341,960	2,739,444	5,250,592	0
Medically needy	299,782	49,712	30,251	62,877	156,942	0	1,689,783	459,367	251,361	247,678	731,377	0
Poverty-related	317,673	14,334	14,459	91,721	191,170	5,989	1,639,436	125,714	118,368	454,059	881,584	59,711
Other/unknown	3,182,605	892	18,327	2,272,093	891,293	0	21,881,483	7,187	161,823	17,163,794	4,548,679	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	4,499,194	72,003	437,337	2,593,052	1,390,873	5,929	33,714,274	682,284	4,737,742	19,450,678	8,784,118	59,452
FFS part year, with Rx claims	329,512	1,390	17,294	103,606	207,182	40	1,407,465	8,063	100,438	438,147	860,620	197
FFS part year, no Rx claims	814,012	1,020	8,492	239,535	564,945	20	2,523,205	4,167	35,332	716,150	1,767,494	62

Table ND2 Nondual Beneficiaries

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

Nondual Beneficiaries

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

Beneficiary	Percentage with at	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$ ^c	FFS \$ ^d	Beneficiaries
All	32.5 %	3.2	\$281	\$87	\$1,773	15.8 %	5,642,718
Age							
5 and younger	33.2	1.2	45	36	1,165	3.9	974,623
6-14	27.7	1.7	138	83	1,505	9.2	772,516
15-20	25.7	1.3	107	82	1,188	9.0	898,823
21-44	30.9	2.2	208	94	1,313	15.9	2,458,046
45-64	54.5	16.8	1,562	93	6,284	24.8	455,109
65-74	70.5	17.3	1,398	81	6,233	22.4	52,866
75-84	66.8	18.0	1,419	79	7,180	19.8	23,622
85 and older	47.2	14.4	1,006	70	7,691	13.1	7,097
Unknown	0.0	0.0	0	0	34	0.0	16
Basis of Eligibility ^e							
Aged	66.4	15.8	1,262	80	5,966	21.1	74,413
Disabled	75.2	23.7	2,410	102	12,267	19.6	463,123
Adults	27.6	1.2	78	68	590	13.3	2,936,193
Children	28.7	1.2	63	53	972	6.5	2,163,000
Unknown	68.1	11.3	1,243	110	7,893	15.7	5,989
Gender							
Female	33.1	3.0	241	81	1,447	16.6	3,831,525
Male	31.2	3.8	365	97	2,463	14.8	1,811,185
Unknown	0.0	0.0	0	0	108	0.0	8
Race							
White	38.4	5.8	540	94	2,917	18.5	1,267,500
African American	32.8	4.5	414	92	2,884	14.4	468,867
Other/unknown	30.5	2.2	180	81	1,269	14.2	3,906,351
Use of Nursing							
Facilities ^f							
Entire year	93.2	73.0	5,290	73	74,643	7.1	6,886
Part year	95.5	53.6	4,386	82	55,860	7.9	8,832
None	32.3	3.1	268	88	1,599	16.8	5,627,000
Maintenance Assistance Status							
Cash	44.5	7.1	647	92	3,720	17.4	1,842,658
Medically needy	37.5	5.3	448	84	3,861	11.6	299,782
Poverty related	33.5	2.3	180	77	1,996	9.0	317,673
Other/unknown	24.9	0.9	63	71	428	14.6	3,182,605

Table ND3 Nondual Beneficiaries

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving fost care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

					N	umber of Rx, Per	centage with:			_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	A Mean Rx \$	Rx \$ as a rcentage of Il Medicaid FFS \$ ^c	None	0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.5	\$42	15.8 %	67.5 %	26.0 %	2.6 %	2.8 %	0.9 %	0.2 %	\$266	5,642,718	37,644,944
Age												
5 and younger	0.3	10	3.9	66.8	29.9	2.3	0.8	0.1	0.0	251	974,623	4,524,994
6-14	0.3	23	9.2	72.3	24.2	2.1	1.2	0.2	0.0	252	772,516	4,618,088
15-20	0.2	16	9.0	74.3	23.3	1.4	0.9	0.1	0.0	176	898,823	6,074,316
21-44	0.3	29	15.9	69.1	26.9	1.8	1.7	0.5	0.1	181	2,458,046	17,829,163
45-64	2.0	187	24.8	45.5	21.0	8.8	16.8	6.8	1.2	751	455,109	3,807,105
65-74	1.8	146	22.4	29.5	32.3	14.6	18.1	4.8	0.7	649	52,866	507,888
75-84	1.9	148	19.8	33.2	28.4	13.2	18.9	5.5	0.8	749	23,622	226,339
85 and older	1.8	125	13.1	52.8	17.8	8.5	14.0	6.0	1.0	957	7,097	57,024
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	20	16	27
Basis of Eligibility ^e												
Aged	1.7	135	21.1	33.6	31.0	13.7	16.8	4.3	0.6	639	74,413	694,514
Disabled	2.2	229	19.6	24.8	29.9	12.3	22.4	9.0	1.6	1,166	463,123	4,873,512
Adults	0.2	11	13.3	72.4	25.4	1.2	0.9	0.1	0.0	84	2,936,193	20,604,975
Children	0.2	12	6.5	71.3	25.9	2.0	0.8	0.1	0.0	184	2,163,000	11,412,232
Unknown	1.1	125	15.7	31.9	39.9	12.9	13.1	2.1	0.2	792	5,989	59,711
Gender												
Female	0.4	35	16.6	66.9	27.4	2.3	2.5	0.8	0.1	210	3,831,525	26,473,161
Male	0.6	59	14.8	68.8	23.1	3.3	3.5	1.1	0.2	399	1,811,185	11,171,750
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	26	8	33
Race												
White	0.8	71	18.5	61.6	27.4	3.7	5.0	2.0	0.4	383	1,267,500	9,642,029
African American	0.7	62	14.4	67.2	23.6	3.4	4.2	1.4	0.3	429	468,867	3,149,575
Other/unknown	0.4	28	14.2	69.5	25.9	2.1	2.0	0.5	0.1	200	3,906,351	24,853,340
Use of Nursing												
Facilities ^f												
Entire year	6.7	487	7.1	6.8	5.6	6.4	26.0	36.5	18.7	6,865	6,886	74,877
Part year	5.4	442	7.9	4.5	11.8	10.5	32.6	29.6	11.1	5,628	8,832	87,668
None	0.5	40	16.8	67.7	26.1	2.6	2.7	0.8	0.1	240	5,627,000	37,482,399
Maintenance Assistance Status												
Cash	1.0	96	17.4	55.5	30.2	5.1	6.6	2.3	0.4	551	1,842,658	12,434,242
Medically needy	0.9	79	11.6	62.5	24.0	5.5	6.0	1.7	0.3	685	299,782	1,689,783
Poverty related	0.5	35	9.0	66.5	27.8	2.8	2.3	0.5	0.1	387	317,673	1,639,436
Other/unknown	0.1	9	14.6	75.1	23.6	0.8	0.4	0.1	0.0	62	3,182,605	21,881,483

Table ND4 Nondual Beneficiaries

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

Beneficiary		All Rx		Patented Br	and-Name	Drugs	Off-Patent B	Brand-Name	Drugs	Gen	eric Drugs	
-	Number			Number			Number			Number		
Beneficiary Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.5	\$42	\$87	0.2	\$31	\$164	0.0	\$5	\$110	0.3	\$7	\$26
Age												
5 and younger	0.3	10	36	0.0	6	122	0.0	1	49	0.2	3	14
6-14	0.3	23	83	0.1	18	158	0.0	2	103	0.1	3	21
15-20	0.2	16	82	0.1	12	147	0.0	2	94	0.1	2	25
21-44	0.3	29	94	0.1	20	176	0.0	4	104	0.2	5	30
45-64	2.0	187	93	0.8	136	171	0.2	22	128	1.0	28	28
65-74	1.8	146	81	0.9	114	131	0.1	11	94	0.8	21	25
75-84	1.9	148	79	0.9	117	125	0.1	10	86	0.8	21	25
85 and older	1.8	125	70	0.8	95	118	0.1	10	78	0.9	21	24
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility ^d												
Aged	1.7	135	80	0.8	107	126	0.1	9	88	0.7	18	25
Disabled	2.2	229	102	0.9	171	190	0.2	25	130	1.1	32	28
Adults	0.2	11	68	0.1	7	112	0.0	2	85	0.1	2	30
Children	0.2	12	53	0.1	8	126	0.0	1	78	0.1	2	16
Unknown	1.1	125	110	0.4	95	227	0.1	8	95	0.6	22	35
Gender												
Female	0.4	35	81	0.2	25	149	0.0	4	102	0.2	6	27
Male	0.6	59	97	0.2	45	189	0.0	6	127	0.3	8	26
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	0.8	71	94	0.3	52	171	0.1	9	125	0.4	11	27
African American	0.7	62	92	0.2	46	191	0.1	6	114	0.4	9	24
Other/unknown	0.4	28	81	0.1	20	152	0.0	3	97	0.2	5	26
Use of Nursing Facilities ^e												
Entire year	6.7	487	73	2.2	329	147	0.6	52	83	3.8	104	27
Part year	5.4	442	82	1.9	313	168	0.5	47	102	3.0	81	27
None	0.5	40	88	0.2	29	165	0.0	5	111	0.2	6	26
Maintenance Assistance Status												
Cash	1.0	96	92	0.4	71	177	0.1	11	123	0.6	14	25
Medically needy	0.9	79	84	0.4	61	152	0.1	7	98	0.5	12	25
Poverty related	0.5	35	77	0.2	26	166	0.0	3	100	0.3	6	23
Other/unknown	0.1	9	71	0.1	6	113	0.0	1	79	0.1	2	33

Table ND5 Nondual Beneficiaries

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In California, 1.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES. CALIFORNIA. 2004

		er of Rx	•		\$ per Benefit Month Among Users Φ Φ					\$ pe	r Rx					Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$		As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$21	\$15	\$3	\$3	\$82	\$214	\$119	\$18	2,100,512	\$171,767,698	913,332	16.2 %	8,281,365
Biologicals	0.2	0.2	0.0	0.0	245	201	9	35	1033	1,026	3,790	898	10,733	11,084,056	4,578	0.1	45,321
Antineoplastic Agents	0.4	0.1	0.0	0.3	139	103	5	31	321	825	288	107	60,850	19,548,827	13,296	0.2	140,353
Endocrine/Metabolic Drugs	0.4	0.2	0.1	0.1	29	17	6	6	82	115	82	45	2,356,915	193,475,995	697,898	12.4	6,606,239
Cardiovascular Agents	0.9	0.4	0.1	0.5	62	47	3	12	66	114	57	25	2,393,822	157,391,433	243,726	4.3	2,558,766
Respiratory Agents	0.4	0.2	0.0	0.2	24	19	0	5	59	97	76	23	1,838,945	108,585,574	473,403	8.4	4,523,940
Gastrointestinal Agents	0.4	0.2	0.0	0.2	52	41	7	5	117	180	168	26	981,336	114,991,962	212,296	3.8	2,203,264
Genitourinary Agents	0.2	0.1	0.0	0.1	11	7	2	2	59	81	47	35	370,692	21,944,460	206,093	3.7	1,965,050
CNS Drugs	0.9	0.4	0.1	0.4	124	99	13	12	134	226	115	32	2,975,841	399,882,714	308,138	5.5	3,228,684
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.5	0.4	0.0	0.1	60	50	6	4	124	136	138	53	166,013	20,560,378	32,093	0.6	343,985
Neurological Agents	0.4	0.4	0.0	0.1	130	127	1	2	292	355	113	22	34,169	9,979,801	6,890	0.1	76,885
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	25	17	2	6	63	187	394	19	2,167,149	135,993,286	554,122	9.8	5,352,251
Neuromuscular Agents	0.7	0.2	0.1	0.4	73	42	18	12	98	182	146	32	1,196,804	117,072,518	147,684	2.6	1,607,418
Nutritional Products	0.2	0.0	0.0	0.2	4	0	0	4	17	38	31	16	205,250	3,442,275	102,152	1.8	902,663
Hematological Agents	0.4	0.1	0.0	0.3	77	69	2	6	174	520	71	22	235,122	40,919,391	51,222	0.9	529,336
Topical Products	0.2	0.1	0.0	0.2	9	5	1	3	37	84	67	18	949,561	35,131,962	420,879	7.5	3,833,405
Miscellaneous Products	0.3	0.2	0.0	0.1	65	50	8	6	236	320	348	66	76,835	18,137,582	30,768	0.5	279,511
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	13	0	0	0	69	0	0	0	46,648	3,221,237	23,246	0.4	243,119
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	18,167,197	1,583,131,149	n.a.	n.a.	n.a.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In California, 1.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{9, b, c} NONDUAL BENEFICIARIES, CALIFORNIA, 2004

			Users		Ar	mong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Rx	\$ per Benefit Month
ANTIPSYCHOTICS	\$264,963,470	162,623	2.9 %	1,820,741	0.6	\$254	\$146
ANTICONVULSANT	106,302,354	140,511	2.5	1,545,827	0.6	117	69
ANTIDEPRESSANTS	100,716,047	258,551	4.6	2,782,841	0.5	80	36
ANTIVIRAL	97,687,507	55,040	1.0	562,857	0.4	394	174
CONTRACEPTIVES	96,592,536	541,215	9.6	5,044,302	0.2	83	19
ULCER DRUGS	91,996,197	207,391	3.7	2,194,778	0.3	126	42
ANTIASTHMATIC	68,261,951	361,035	6.4	3,549,252	0.3	68	19
ANTIHYPERLIPIDEMIC	67,261,143	120,179	2.1	1,308,669	0.4	130	51
ANALGESICS - ANTI-INFLAMMATORY	65,744,762	428,977	7.6	4,255,018	0.2	69	15
ANTIDIABETIC	64,338,131	149,988	2.7	1,569,724	0.5	87	41
Total	1,023,864,098	2,425,510		24,634,009	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{8, b, c}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

	All Top 10 D	rug Groups		ANTIPS	SYCHOTICS				ANTICO	ONVULSANT		
Beneficiary Characteristics	Number of Rx	Rx\$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per
All	8,544,804	\$1,023,864,098	162,623	2.9 %	1,820,741	0.6	\$146	140,511	2.5 %	1,545,827	0.6	\$69
Female	5,455,386	596,097,277	81,705	2.1	911,620	0.5	128	79,730	2.1	875,117	0.6	65
Disabled	3,092,941	391,210,609	65,190	28.8	748,795	0.6	141	61,638	27.2	701,191	0.6	
5 and younger	18,794	1,640,712	46	0.7	542	0.5	88	644	9.8	7,105	0.6	
6-14	62,426	8,000,583	1,181	8.2	13,453	0.5	125	2,540	17.7	29,176	0.7	105
15-20	72,858	9,346,247	2,242	17.1	25,458	0.5	124	2,681	20.4	30,314	0.7	105
21-44	781,273	109,172,961	25,278	39.7	288,535	0.6	142	20,982	33.0	236,980	0.6	
45-64	2,083,226	254,679,675	35,453	28.7	409,410	0.6	141	33,916	27.4	387,632	0.6	
65-74	69,087	7,845,382	922	19.4	10,617	0.7	157	810	17.0	9,254	0.6	
75-84	4,771	485,368	65	14.9	744	0.7	92	58	13.3	656	0.6	
	506	39,681	3	2.5	36	0.3	36	7	5.9	74	0.5	
85 and older Other Eligibles	2,362,445	204,886,668	16,515	0.5	162,825	0.4	67	18,092	0.5	173,926	0.4	
5 and younger	99,212	3,824,856	179	0.0	1,875	0.2	41	372	0.1	3,244	0.5	
6-14	131,065	11,118,394	3,035	8.0	33,378	0.5	109	1,858	0.5	19,229	0.5	
15-20	325,488	26,404,564	3,411	0.5	34,615	0.4	84	2,326	0.4	22,678	0.5	
21-44	1,335,555	113,263,629	6,428	0.3	58,153	0.3	43	8,110	0.4	73,953	0.4	40
45-64	190,431	19,302,292	1,732	1.1	15,873	0.3	43	2,589	1.7	22,899	0.4	40
65-74	169,433	19,195,524	802	2.8	8,929	0.3	63	1,667	5.9	18,711	0.3	26
	91,554	9,883,325	626	4.6	6,830	0.4	60	960	7.0	10,884	0.4	25
75-84	19,707	1,894,084	302	6.8	3,172	0.5	68	210	4.7	2,328	0.4	26
85 and older Male	3,089,418	427,766,821	80,918	4.5	909,121	0.6	164	60,781	3.4	670,710	0.6	74
	2,348,964	357,727,551	67,660	28.6	•	0.6	172		21.3	571,333	0.6	78
Disabled	25,727	2,342,569	132	1.5	771,247 1,454	0.6	61	50,474 745	8.3	8,120	0.7	
5 and younger	25,727 116,617	2,342,569 15,421,415	3,891	1.5 14.6		0.4	134	4,100	6.3 15.4	46,916	0.6	97
6-14	108,620	16,492,829	3,891 4,540	21.4	44,334	0.5	155	4,100 3,653	17.3	41,531	0.7	106
15-20	773,418	139,246,101	32,385	42.8	51,353 368,536	0.6	182	20,003	26.5	226,368	0.7	86
21-44	1,286,619	, ,		26.0	,	0.6	170		20.5	,		
45-64	1,286,619 34,168	180,000,388 3,847,794	26,185 474	26.0 16.1	299,549 5,430	0.6	163	21,501 436	21.3 14.8	242,958 5,012	0.6 0.6	
65-74	3,452	3,647,794	474	12.8	5, 4 30 511	0.7	122	436 32	9.3	380	0.6	
75-84	3,452	36,229	9	10.6	80	0.8	40	32 4	9.3 4.7	48	0.8	
85 and older Other Eligibles	740,454	70,039,270	13.258	0.8	137,874	0.5	115	10,307	4.7 0.7	99,377	0.5	
Other Eligibles			-,		,		58	*	0.7	*		
5 and younger	134,690	5,993,004	324	0.1 1.6	3,416	0.3		511		4,548	0.5	
6-14	179,589	18,554,883	5,977		65,685	0.6	131	2,795	0.8	29,314	0.6	
15-20	107,703	11,275,388	4,088	1.8	42,148	0.5	122	2,170	1.0	21,549	0.5	64
21-44	103,728	10,425,275	1,442	0.4	12,089	0.3	73 50	2,237	0.6	18,369	0.4	
45-64	65,877	7,460,093	423	0.6	3,555	0.3	59 70	1,025	1.4	8,249	0.4	
65-74	87,271	9,626,691	484	2.9	5,326	0.4	76	936	5.6	10,253	0.4	
75-84	49,792	5,555,806	358	3.9	3,969	0.4	68	520	5.7	5,862	0.4	
85 and older	11,804	1,148,130	162	6.6	1,686	0.5	72	113	4.6	1,233	0.4	26
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7A Nondual Beneficiaries

- a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7A Nondual Beneficiaries

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

		ANTIDE	PRESSANTS				AN	ΓIVIRAL				CONTR	ACEPTIVES		
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per
All	258,551	4.6 %	2,782,841	0.5	\$36	55,040	1.0 %	562,857	0.4	\$174	541,215	9.6 %	5,044,302	0.2	\$19
Female	172,284	4.5	1,843,417	0.4	36	30,439	0.8	309,502	0.3	115	541,064	14.1	5,042,916	0.2	19
Disabled	110,116	48.6	1,252,767	0.5	39	10,709	4.7	121,957	0.5	212	9,291	4.1	107,649	0.3	19
5 and younger	28	0.4	317	0.3	12	58	0.9	642	0.5	56	1	0.0	12	0.1	5
6-14	971	6.8	10,999	0.5	32	265	1.9	3,119	0.6	244	129	0.9	1,490	0.2	
15-20	2,403	18.3	26,851	0.4	34	183	1.4	2,092	0.3	106	1,550	11.8	17,844	0.2	
21-44	31,425	49.4	353,811	0.5	39	4,100	6.4	46,142	0.5	219	6,622	10.4	76,781	0.3	
45-64	73,709	59.6	842,581	0.5	39	6,002	4.9	68,807	0.5	211	989	8.0	11,522	0.3	21
65-74	1,486	31.2	17,118	0.5	33	94	2.0	1,074	0.3	133	0	0.0	0	0.0	
	83	19.0	964	0.5	36	7	1.6	81	0.1	8	0	0.0	0	0.0	0
75-84	11	9.3	126	0.4	30	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	62,168	1.7	590,650	0.3	29	19,730	0.5	187,545	0.2	51	531,773	14.8	4,935,267	0.2	
_	98	0.0	971	0.3	11	218	0.0	1,730	0.3	48	66	0.0	446	0.2	16
5 and younger	4,088	1.1	43,607	0.4	30	622	0.2	6,367	0.3	112	1,519	0.4	12,017	0.2	16
6-14	8,398	1.3	82,958	0.4	28	2,560	0.4	23,739	0.2	31	107,422	16.8	940,290	0.2	17
15-20	34,159	1.8	313,714	0.3	29	14,249	0.7	135,125	0.3	48	413,319	21.5	3,892,829	0.2	20
21-44	9,804	6.3	86,871	0.4	33	1,492	1.0	13,880	0.3	100	9,437	6.0	89,576	0.2	20
45-64	3,390	11.9	37,602	0.3	23	382	1.3	4,337	0.2	59	7	0.0	75	0.2	18
65-74	1,789	13.0	20,196	0.3	26	163	1.2	1,856	0.1	17	3	0.0	34	0.2	14
75-84	442	10.0	4,731	0.5	33	44	1.0	511	0.1	10	0	0.0	0	0.0	0
85 and older	86,267	4.0	939.424	0.5	37	24 604	1 1	253.355	0.6	246	151	0.0	1,386	0.2	22
Male	,	4.8	,	0.5		24,601	1.4 7.6	196,176	0.6	246 296			,	0.2	31
Disabled	64,497	27.3	726,648		39	17,987					41 0	0.0	482 0		0
5 and younger	45	0.5	505	0.4	18	66	0.7	718	0.5	67	0	0.0	0	0.0	0
6-14	2,505	9.4	28,172	0.5	34	345	1.3	4,026	0.6	198	1	0.0		0.0	
15-20	3,264	15.4	36,756	0.5	41	234	1.1	2,676	0.4	215	1 24	0.0	12 284	0.1 0.3	10 26
21-44	22,098	29.2	247,753	0.5	41	8,425	11.1	90,029	0.6	282		0.0	_		
45-64	35,898	35.6	405,499	0.5	38	8,817	8.7	97,585	0.7	317	16	0.0	186	0.4	42
65-74	615	20.9	7,141	0.5	33	96	3.3	1,094	0.5	232	0	0.0	0	0.0	0
75-84	59	17.2	676	0.5	31	4	1.2	48	0.1	7	0	0.0	0	0.0	0
	13	15.3	146	0.3	20	0	0.0	0	0.0	0	ŭ	0.0	0	0.0	0
85 and older Other Eligibles	21,770	1.4	212,776	0.4	31	6,614	0.4	57,179	0.3	75 27	110	0.0	904	0.2	16
5 and younger	182	0.0	1,900	0.3	14	225	0.0	1,903	0.3	37	3	0.0	8	0.4	30
6-14	5,762	1.6	62,144	0.5	34	469	0.1	4,952	0.4	145	1	0.0	12	0.1	4
15-20	5,750	2.6	57,494	0.4	34	742	0.3	6,331	0.2	60	44	0.0	351	0.2	
21-44	5,369	1.4	45,619	0.3	28	4,035	1.0	33,506	0.3	58 450	58	0.0	500	0.2	
45-64	2,373	3.2	19,831	0.3	30	770	1.0	6,247	0.4	159	4	0.0	33	0.1	12
65-74	1,286	7.7	14,269	0.3	26	240	1.4	2,711	0.2	50	0	0.0	0	0.0	0
75-84	786	8.6	8,744	0.4	27	111	1.2	1,270	0.1	33	0	0.0	0	0.0	0
85 and older	262	10.6	2,775	0.4	31	22	0.9	259	0.2	34	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B Nondual Beneficiaries

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7B Nondual Beneficiaries

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

		ULCE	R DRUGS				ANTIA	STHMATIC				ANTIHYP	ERLIPIDEMIC)	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Rx \$ per Benefit Month
All	207,391	3.7 %	2,194,778	0.3	\$42	361,035	6.4 %	3,549,252	0.3	\$19	120,179	2.1 %	1,308,669	0.4	\$51
Female	133,266	3.5	1,415,360	0.3	42	198,451	5.2	1,985,993	0.3	19	72,515	1.9	794,364	0.4	51
Disabled	78,968	34.9	904,497	0.4	48	86,472	38.2	988,979	0.3	25	47,667	21.0	547,863	0.4	53
5 and younger	677	10.3	7,208 13,074	0.4 0.4	29	2,786	42.5	30,337	0.3	26 25	8	0.1	91	0.2	13 36
6-14	1,128 1,343	7.9 10.2	15,527	0.4	41 32	4,411 2,849	30.8 21.7	51,212 33,154	0.3	25 20	27 61	0.2 0.5	316 720	0.4 0.4	36
15-20	16,231	25.5	185,572	0.3	42	2,649 19.613	30.8	224,225	0.3	20	5.098	8.0	58.404	0.4	45
21-44	57,375	46.4	657,835	0.3	50	54,925	30.6 44.4	628,735	0.3	27	40,523	32.8	465,706	0.4	53
45-64	2,050	43.1	23,427	0.4	50 51	1,766	37.1	19,930	0.4	27 27	1,820	38.2	21,109	0.4	59
65-74	139	31.9	1,580	0.4	55	1,700	25.0	1,252	0.4	29	1,820	27.1	1,390	0.4	60
75-84	25	21.2	274	0.5	49	13	11.0	134	0.4	20	12	10.2	1,330	0.6	67
85 and older Other Eligibles	54.298	1.5	510,863	0.3	31	111.979	3.1	997.014	0.2	14	24.848	0.7	246.501	0.3	47
Other Eligibles	2,602	0.5	18,053	0.2	9	35,677	7.5	278,814	0.2	10	58	0.0	614	0.1	7
5 and younger	3,506	1.0	32,777	0.2	11	22,934	6.3	217,043	0.2	14	50	0.0	542	0.2	
6-14	5,192	0.8	48,431	0.2	15	12,861	2.0	120,929	0.2	12	136	0.0	1,273	0.2	
15-20	20,243	1.1	182,045	0.2	28	26,950	1.4	244,136	0.2	14	4,161	0.2	37,197	0.3	35
21-44	8,588	5.5	72,533	0.3	40	6,573	4.2	58,084	0.3	21	6,289	4.0	50,729	0.3	46
45-64	8.743	30.8	96,311	0.3	39	3.664	12.9	40.878	0.3	23	9.698	34.1	106.101	0.4	51
65-74	4,440	32.3	49,953	0.3	45	2,645	19.3	29,771	0.3	24	3,986	29.0	44,792	0.4	53
75-84	984	22.2	10,760	0.4	47	675	15.2	7,359	0.3	21	470	10.6	5,253	0.4	55
85 and older	==				40					4.0	4= 004				
Male	74,125	4.1	779,418	0.3	43	162,584	9.0	1,563,259	0.3	19	47,664	2.6	514,305	0.4	52
Disabled	48,485	20.5	548,232	0.4	47	58,901	24.9	669,001	0.4	26	33,204	14.0	378,609	0.4	53
5 and younger	809	9.0	8,734	0.4	31	4,338	48.3	47,432	0.3	25	15	0.2	161	0.3	13
6-14	1,647	6.2	19,001	0.4	39	8,284	31.0	95,645	0.3	23	37	0.1	428	0.4	34
15-20	1,509	7.1	17,416	0.3	38	4,134	19.5	48,020	0.3	21	133	0.6	1,525	0.4	35
21-44	12,266	16.2	138,721	0.4	45	11,097	14.7	126,316	0.3 0.4	20	6,144	8.1	70,692	0.4	46 55
45-64	31,120 1,013	30.9 34.4	351,348 11,656	0.4 0.4	49 45	29,997 940	29.8 31.9	339,723 10,668	0.4	29 29	25,883 885	25.7 30.0	294,266 10,305	0.4 0.4	55 57
65-74	1,013	30.6	1.194	0.4	45 49	940	26.8	1,016	0.4	29 19	96	28.0	1,114	0.4	57 58
75-84	16	18.8	1,194	0.4	54	19	20.6	181	0.3	24	11	12.9	1,114	0.5	83
85 and older Other Eligibles	25,640	1.6	231,186	0.4	32	103,683	6.6	894,258	0.3	14	14,460	0.9	135,696	0.7	49
Other Eligibles	3,329	0.7	23,417	0.3	11	50,456	10.4	392,777	0.2	12	65	0.0	706	0.4	5
5 and younger	2,891	0.8	26,995	0.2	11	30,861	8.4	288,461	0.2	15	59	0.0	536	0.1	24
6-14	2,599	1.2	24,059	0.2	18	9,613	4.3	92,527	0.2	15	148	0.1	1,289	0.3	27
15-20	6,366	1.6	52,925	0.2	36	5,396	1.4	45,663	0.2	17	2,964	0.8	23,896	0.3	
21-44	3,552	4.8	27,646	0.3	44	2,197	3.0	18,256	0.3	22	3,924	5.3	29,242	0.4	47
45-64	4,033	24.1	44,283	0.3	42	2,769	16.5	30,153	0.3	26	4,777	28.5	51,687	0.4	53
65-74	2,294	25.2	25,520	0.3	46	1,882	20.7	20,784	0.3	25	2,229	24.5	24,997	0.4	55
75-84	576	23.4	6,341	0.4	46	509	20.7	5,637	0.3	24	294	11.9	3,343	0.4	
85 and older								,					•		
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C Nondual Beneficiaries

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7C Nondual Beneficiaries

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, CALIFORNIA, 2004

	ANAL	GESICS - A	NTI-INFLAM	MATORY			ANTI	DIABETIC				
Beneficiary	Number of	Users as % of All	Number of Benefit Months Among	of Rx	Mean Rx \$ per Benefit	Number of	Users as % of All	Number of Benefit Months Among	of Rx	Mean Rx \$ per Benefit	Number of	Number o
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month		Benefit Months
All	428,977	7.6 %	4,255,018	0.2	\$16	149,988	2.7 %	1,569,724	0.5	\$41	5,642,718	37,644,944
Female	276,629	7.2	2,742,907	0.2	17	94,399	2.5	992,099	0.5	41	3,831,518	26,473,149
Disabled	106,100	46.8	1,224,640	0.3	28	60,249	26.6	684,526	0.5	44	226,531	2,411,896
5 and younger	765	11.7	8,558	0.2	2	16	0.2	175	0.6	68	6,557	
6-14	2,090	14.6	24,524	0.2	8	163	1.1	1,857	0.6	61	14,324	
15-20	2,567	19.6	29,594	0.2	7	391	3.0	4,426	0.5	44	13,111	140,262
21-44	24,318	38.2	279,017	0.2	18	7,868	12.4	89,504	0.5	40	63,649	,
45-64	73,641	59.6	851,044	0.3	32	49,439	40.0	561,273	0.5	44	123,576	
65-74	2,534	53.2	29,716	0.3	33	2,215	46.5	25,568	0.5	42	4,760	
75-84	166	38.1	1,960	0.3	37	145	33.3	1,607	0.6	46	436	,
	19	16.1	227	0.3	22	12	10.2	116	0.5	24	118	975
85 and older Other Eligibles	170,529	4.7	1,518,267	0.2	9	34,150	0.9	307,573	0.4	36	3,604,987	
_	26,890	5.7	223,656	0.2	2	93	0.0	776	0.5	49	473,681	2,159,582
5 and younger	20,872	5.7	189,591	0.1	2	608	0.2	5,000	0.6	56	363,053	2,073,993
6-14	23,007	3.6	199,739	0.2	2	993	0.2	8,375	0.5	44	639,791	4,350,968
15-20	65,885	3.4	569,656	0.2	6	10,283	0.5	83,190	0.4	32	1,925,136	14,002,701
21-44	15,485	9.9	132,219	0.2	19	9,188	5.9	69,562	0.4	40	156,749	1,036,892
45-64	12,106	42.6	132,978	0.3	28	8,504	29.9	91,002	0.4	36	28,407	269,292
65-74	5,444	39.6	60,964	0.3	32	3,934	28.6	43,610	0.4	33	13,737	132,716
75-84 85 and older	840	18.9	9,464	0.3	34	547	12.3	6,058	0.5	30	4,433	35,109
Male	152,348	8.4	1,512,111	0.2	13	55,589	3.1	577,625	0.5	41	1,811,176	11,171,735
Disabled	62,638	26.5	719,569	0.3	19	38,018	16.1	425,790	0.5	42	236,592	
2.00.0.00	1,061	11.8	12,056	0.1	2	24	0.3	249	0.7	62	8,977	, ,
5 and younger	3,161	11.8	36,807	0.1	4	187	0.7	2,116	0.7	56	26,701	284,201
6-14	2,814	13.3	32,541	0.1	4	359	1.7	3,992	0.6	46	21,176	,
15-20	16,509	21.8	189,172	0.2	13	6,404	8.5	72,084	0.5	39	75,579	•
21-44	37,725	37.4	432,975	0.3	24	29,929	29.7	334,570	0.5	42	100,783	
45-64	1,236	41.9	14,467	0.3	26	985	33.4	11,291	0.5	40	2,948	
65-74	1,230	35.0	1,410	0.3	36	123	35.4	1,424	0.5	38	2,946	,
75-84	120	14.1	1,410	0.4	35	7	8.2	1,424	0.3	23	343 85	,
85 and older Other Eligibles	89,710	5.7	792,542	0.3	35 7	7 17,571	0.2 1.1	151,835	0.3	23 39	05 1,574,584	
Other Eligibles	30,011	5.7 6.2	792,542 249,814	0.2	2	17,571	0.0	679	0.4	39 39	1,574,584 485,401	2,223,991
5 and younger	,			0.2	2	523			0.5	63	,	, ,
6-14	18,906	5.1 5.5	172,379			523 621	0.1	4,451 5,110			368,437	, ,
15-20	12,266	5.5	112,416	0.1	2 7		0.3	5,110	0.6	58 37	224,745	, ,
21-44	13,972	3.5	114,946	0.2		4,242	1.1	31,748	0.4		393,682	
45-64	6,001	8.1	48,312	0.2	16	5,500	7.4	38,449	0.4	40	74,001	414,254
65-74	5,328	31.8	58,687	0.2	25	4,181	25.0	44,717	0.4	36	16,751	153,788
75-84	2,753	30.2	30,713	0.3	30	2,061	22.6	22,855	0.4	36	9,106	,
85 and older	473	19.2	5,275	0.3	31	355	14.4	3,826	0.5	32	2,461	20,292
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	24	60

Table ND7D Nondual Beneficiaries

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Table ND7D Nondual Beneficiaries

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC $^{a,\,b}$

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

Beneficiary	Du [©] non Donofit Month	Number of Rx per Benefit	Number of All-Year Nursing	Benefit Months Among All- Year Nursing Facility
Characteristics All	Rx \$ per Benefit Month \$487	Month 6.7	Facility Residents 6,886	Residents 74,877
	Ψ.σ.	•	0,000	,0
Age		7.0	5.000	== 000
0-64	525	7.0	5,082	55,696
65-74	459	6.7	794	8,697
75-84	324	5.7	559	5,982
85 and older	283	5.1	451	4,502
Unknown	0	0.0	0	0
Gender				
Female	493	6.9	3,353	36,818
Male	480	6.5	3,533	38,059
Unknown	0	0.0	0	0
Race				
White	511	6.8	2,993	32,144
African American	480	6.8	1,193	13,052
Other/unknown	463	6.6	2,700	29,681
Basis of Eligibility ^c				
Aged	337	5.8	1,357	14,335
Disabled	523	6.9	5,460	59,907
Adults	509	7.8	29	191
Children	382	6.9	36	402
Unknown	764	11.9	4	42

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY A, b, c, d, e NONDUAL BENEFICIARIES, CALIFORNIA, 2004

		er of Ro	ng Use			er Bene Among		th		\$ per	Rx			_		Users	
Therapeutic Category	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	F Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.4	0.2	0.0	0.2	\$51	\$36	\$8	\$7	\$120	\$200	\$177	\$35	19,081	\$2,290,424	3,995	58.0 %	44,590
Biologicals	0.1	0.1	0.0	0.0	11	10	0	1	113	180	88	30	1,140	128,522	957	13.9	11,185
Antineoplastic Agents	0.5	0.1	0.0	0.5	84	24	3	57	156	429	273	121	3,022	471,873	523	7.6	5,615
Endocrine/Metabolic Drugs	1.3	0.4	0.2	0.7	61	38	9	14	48	92	48	21	36,494	1,764,185	2,631	38.2	29,132
Cardiovascular Agents	1.9	0.6	0.1	1.2	74	46	5	23	38	76	40	19	86,198	3,302,539	4,034	58.6	44,373
Respiratory Agents	1.3	0.4	0.0	0.9	61	33	1	26	46	88	58	29	37,523	1,734,573	2,558	37.1	28,327
Gastrointestinal Agents	1.2	0.5	0.1	0.6	86	66	6	14	74	129	89	24	46,395	3,419,225	3,629	52.7	39,582
Genitourinary Agents	0.6	0.3	0.0	0.3	39	23	3	12	60	83	70	37	8,805	525,856	1,204	17.5	13,602
CNS Drugs	1.9	0.9	0.2	0.7	229	183	21	25	123	211	87	34	99,281	12,255,983	4,805	69.8	53,560
Stimulants/Anti-obesity/Anorexia	0.5	0.2	0.0	0.4	41	31	0	10	75	170	31	28	188	14,084	30	0.4	343
Miscellaneous Psychological/																	
Neurological Agents	8.0	0.8	0.0	0.0	203	203	0		248	249	0	11	3,879	962,185	432	6.3	4,749
Analgesics and Anesthetics	1.0	0.4	0.0	0.6	67	50	4	13	68	140	142	22	30,702	2,093,874	2,857	41.5	31,195
Neuromuscular Agents	1.6	0.3	0.3	1.0	109	41	29	39	68	130	106	38	67,036	4,562,257	3,710	53.9	41,874
Nutritional Products	0.6	0.0	0.0	0.6	12	0	0	12	19	21	40	19	11,149	216,955	1,591	23.1	17,475
Hematological Agents	1.2	0.2	0.1	0.9	75	62	2	11	61	264	27	12	25,593	1,564,026	1,949	28.3	20,944
Topical Products	0.6	0.1	0.1	0.4	21	9	5	7	37	69	70	19	21,102	784,696	3,337	48.5	37,893
Miscellaneous Products	0.4	0.0	0.0	0.3	26	12	1	14	73	261	382	43	2,973	215,959	759	11.0	8,288
Unknown Therapeutic Category	0.4	0.0	0.0	0.0	21	0	0	0	54	0	0	0	2,204	119,546	514	7.5	5,723
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	502,765	36,426,762	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In California, 1.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND9 Nondual Beneficiaries

TABLE ND.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP $^{a, b, c, d}$

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

			Users		A	mong Users	
			As a Percentage of All-Year				
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$9,561,906	4,388	63.7 %	50,103	0.9	\$211	\$191
ANTICONVULSANT	3,641,564	4,022	58.4	45,665	1.1	75	80
ULCER DRUGS	2,794,378	3,729	54.2	41,088	0.8	87	68
ANTIDEPRESSANTS	2,053,510	3,319	48.2	37,177	0.8	66	55
ANTIDIABETIC	1,602,652	3,246	47.1	36,318	0.9	49	44
ANTIASTHMATIC	1,451,335	3,560	51.7	39,531	0.8	45	37
ANALGESICS - Narcotic	1,111,391	2,835	41.2	30,753	0.6	58	36
ANTIHYPERTENSIVE	1,055,348	2,888	41.9	32,179	0.8	42	33
ANTIHYPERLIPIDEMIC	1,006,056	1,243	18.1	14,133	0.8	87	71
MISC PSYCHOTHERAPEUTIC AND							
NEUROLOGICAL	962,346	457	6.6	5,062	0.8	248	190
Total	25,240,486	29,687		332,009	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, CALIFORNIA, 2004

	All Top 10 Dr	ug Groups		ANTIPS	SYCHOTICS				ANTICONVULSANT				
Beneficiary Characteristics	Number of Rx	Rx\$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	
All	281,952	\$25,240,486	4,388	63.7 %	50,103	0.9	\$191	4,022	58.4 %	45,665	1.1	\$80	
Female	142,147	12,837,803	2,234	66.6	25,663	0.9	187	1,875	55.9	21,472	1.1	80	
Disabled	115,844	10,935,266	1,878	75.3	21,780	0.9	200	1,634	65.5	18,768	1.1	84	
	103,488	9,734,535	1,618	72.9	18,782	0.9	201	1,472	66.4	16,924	1.1	85	
64 or younger	11,176	1,116,299	237	99.2	2,723	0.9	206	144	60.3	1,657	1.0	71	
65-74	1,122	80,441	21	63.6	251	0.8	118	17	51.5	185	1.1	61	
75-84	58	3,991	2	40.0	24	0.1	11	1	20.0	2	1.0	28	
85 and older Other Eligibles	26,303	1,902,537	356	41.5	3,883	0.7	115	241	28.1	2,704	0.9	52	
•	1,025	62,444	7	31.8	74	0.3	40	12	54.5	130	0.9	52	
64 or younger	8,932	668,231	119	53.6	1,348	0.8	147	92	41.4	1,075	0.9	56	
65-74	9,825	728,470	127	41.0	1,364	0.7	107	91	29.4	1,008	0.9	51	
75-84	6,521	443,392	103	33.9	1,097	0.7	90	46	15.1	491	0.8	43	
85 and older	400.005	40,400,000	0.454	04.0	04.440	0.0	405	0.447	00.0	04.400	4.4	00	
Male	139,805	12,402,683	2,154	61.0	24,440	0.9	195	2,147	60.8	24,193	1.1	80	
Disabled	121,923	11,086,554	1,934	65.2	22,053	0.9	201	1,969	66.4	22,243	1.1	81	
64 or younger	115,579	10,496,571	1,819	65.1	20,746	0.9	200	1,879	67.2	21,201	1.1	82	
65-74	5,488	529,276	102	70.8	1,165	0.9	231	78	54.2	900	1.1	62	
75-84	822	58,447	12	54.5	140	0.7	117	12	54.5	142	8.0	37	
85 and older	34	2,260	1	25.0	2 207	1.0	185	0	0.0	1.050	0.0	0	
Other Eligibles	17,882	1,316,129	220	38.7	2,387	0.8 0.6	134	178	31.3 51.1	1,950 254	0.9 1.0	62 135	
64 or younger	1,400	92,683	2	4.3	11		55 463	24					
65-74	7,413	546,422	81	42.9	929	1.0	162	82	43.4	937	1.0	55	
75-84	5,647	423,277	81	41.8	875	0.8	128	51	26.3	534	0.8	53	
85 and older	3,422	253,747	56	40.6	572	0.7	97	21	15.2	225	0.7	32	
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, CALIFORNIA, 2004

		ULCE	R DRUGS				ANTIDE	PRESSANTS	3		ANTIDIABETIC				
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	3,729	54.2 %	41,088	8.0	\$68	3,319	48.2 %	37,177	0.8	\$55	3,246	47.1 %	36,318	0.9	\$44
Female Disabled 64 or younge 65-74 75-84 85 and older Other Eligibles 64 or younge 65-74 75-84 85 and older Male Disabled 64 or younge 65-74 75-84 85 and older We have the service of th	1,817 1,345 1,205 123 15 2 472 20 127 171 154 1,912 1,587 1,508 61 17 1	54.2 53.9 54.3 51.5 45.5 40.0 55.0 90.9 57.2 55.2 50.7 54.1 53.5 54.0 42.4 77.3 25.0 57.2	20,199 15,095 13,614 1,312 145 24 5,104 216 1,423 1,866 1,599 20,889 17,307 16,449 666 190 2	0.8 0.8 0.8 0.8 1.1 0.8 0.6 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8	69 70 69 84 66 72 66 47 67 72 59 67 67 80 41 172 67	1,805 1,451 1,317 121 12 1 354 7 112 134 101 1,514 1,308 1,247 50 8 3	53.8 58.2 59.4 50.6 36.4 20.0 41.3 31.8 50.5 43.2 33.2 42.9 44.1 44.6 34.7 36.4 75.0 36.3	20,345 16,454 14,967 1,342 133 12 3,891 78 1,292 1,488 1,033 16,832 14,579 13,903 566 84 26 2,253	0.8 0.9 0.9 0.8 0.7 0.9 0.8 1.5 0.8 0.7 0.8 0.8 0.8 0.8	57 58 58 53 62 69 51 80 48 56 45 54 54 54 56 48 15	1,697 1,311 1,141 152 17 1 386 2 151 160 73 1,549 1,235 1,145 76 12 2 314	50.6 52.5 51.4 63.6 51.5 20.0 45.0 9.1 68.0 51.6 24.0 43.8 41.7 41.0 52.8 54.5 50.0 55.3	18,981 14,694 12,813 1,692 187 2 4,287 23 1,732 1,711 821 17,337 13,838 12,837 857 140 4 3,499	0.9 0.9 0.9 1.0 1.0 0.9 0.7 0.9 0.8 0.8 0.9 0.9 1.0 0.9	46 47 47 46 46 21 40 44 39 35 43 43 46 42 90 39
Other Eligibles	325 29	57.2 61.7	3,582	0.8	67 52	206 7	36.3 14.9	2,253	0.8 1.4	114	314 7	55.3 14.9	3,499 59	0.8	39 25
64 or younge 65-74 75-84 85 and older	110 108 78	58.2 55.7 56.5	1,247 1,155 894	0.8 0.7 0.7	69 72 64	64 72 63	33.9 37.1 45.7	743 800 656	0.9 0.8 0.7	58 44 47	143 110 54	75.7 56.7 39.1	1,636 1,198 606	0.8 0.8 0.7	43 38 34
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, CALIFORNIA, 2004

	ANTIASTHMATIC						ANALGES	SICS - Narcot	ic		ANTIHYPERTENSIVE				
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	of Rx	Mean Rx \$
All	3,560	51.7 %	39,531	0.8	\$37	2,835	41.2 %	30,753	0.6	\$36	2,888	41.9 %	32,179	0.8	\$33
Female	1,731	51.6	19,220	0.7	35	1,507	44.9	16,505	0.6	36	1,431	42.7	15,945	0.8	32
Disabled	1,342	53.8	14,956	8.0	37	1,169	46.9	12,939	0.7	41	975	39.1	10,912	0.8	32
r 64 or younge	1,186	53.5	13,284	0.8	38	1,075	48.5	11,976	0.7	43	860	38.8	9,641	0.8	33
65-74	141 15	59.0 45.5	1,511 161	0.7 0.5	32 19	85 9	35.6 27.3	875 88	0.6 0.5	15 12	101 13	42.3 39.4	1,115 154	0.8 0.8	32 18
75-84	0	0.0	0	0.5	0	0	0.0	00	0.0	0	13	20.0	2	0.6	64
85 and older Other Eligibles	389	45.3	4,264	0.6	27	338	39.4	3,566	0.0	19	456	53.1	5,033	0.3	31
Other Eligibles	30	136.4	324	1.1	68	14	63.6	144	1.2	61	13	59.1	134	0.7	35
64 or younge	87	39.2	988	0.6	30	102	45.9	1,097	0.4	14	144	64.9	1,629	0.8	33
65-74	162	52.3	1,810	0.5	26	119	38.4	1,282	0.4	18	164	52.9	1,835	0.7	29
75-84	110	36.2	1,142	0.4	16	103	33.9	1,043	0.5	17	135	44.4	1,435	0.8	32
85 and older Male	1,829	51.8	20,311	0.9	39	1,328	37.6	14,248	0.6	37	1,457	41.2	16,234	0.8	24
	1,529	51.6 51.3	16,831	0.9	39 41	1,142	37.6 38.5	12,316	0.6	37 41	1,457	39.4	13,076	0.8	34 35
Disabled	1,442	51.6	15,961	1.0	42	1,096	39.2	11,801	0.0	42	1,086	38.9	12,153	0.8	35
64 or younge '	67	46.5	764	0.8	30	39	27.1	436	0.4	21	64	44.4	714	0.8	32
65-74	9	40.9	92	0.3	8	6	27.3	72	0.3	4	16	72.7	188	0.7	27
75-84	2	50.0	14	0.5	15	1	25.0	7	0.4	3	3	75.0	21	0.4	14
85 and older Other Eligibles	309	54.4	3,480	0.6	27	186	32.7	1,932	0.4	12	288	50.7	3,158	0.7	30
r	63	134.0	714	1.0	42	11	23.4	67	8.0	11	8	17.0	53	0.8	27
64 or younge	89	47.1	1,028	0.7	28	57	30.2	665	0.4	11	112	59.3	1,282	8.0	34
65-74 75-84	75	38.7	803	0.5	21	64	33.0	637	0.4	17	104	53.6	1,130	0.7	25
75-84 85 and older	82	59.4	935	0.4	18	54	39.1	563	0.3	7	64	46.4	693	0.7	30
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

Table ND10C Nondual Beneficiaries

TABLE ND.10D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c, d} NONDUAL BENEFICIARIES, CALIFORNIA, 2004

		ANTIHYP	ERLIPIDEMI	С		MISC PSYC	HOTHERAP	EUTIC AND N	NEUROLO	GICAL		
		Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean		All-Year	Benefit Months Among All- Year Nursing
Beneficiary	Number of	Facility	Among	Number	Mean	Number of	Facility	Among		Mean	Facility	Facility
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Residents	Residents
All	1,243	18.1 %	14,133	0.8	\$71	457	6.6 %	5,062	0.8	\$190	6,886	74,877
Female	623	18.6	7,132	0.9	73	254	7.6	2,803	0.7	219	3,353	36,818
Disabled	475	19.0	5,456	0.9	73	118	4.7	1,360	8.0	342	2,495	27,776
	411	18.5	4,728	0.9	73	101	4.6	1,161	8.0	373	2,218	24,772
64 or younger	57	23.8	644	0.9	79	14	5.9	168	0.7	171	239	2,596
65-74	6	18.2	72	0.6	38	3	9.1	31	0.9	115	33	368
75-84	1	20.0	12	1.1	79	0	0.0	0	0.0	0	5	40
85 and older Other Eligibles	148	17.2	1,676	0.8	74	136	15.9	1,443	0.7	104	858	9,042
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	22	221
64 or younger	62	27.9	719	0.8	71	24	10.8	255	0.6	105	222	2,422
65-74	59	19.0	661	0.8	74	64	20.6	688	0.8	107	310	3,327
75-84	27	8.9	296	0.9	79	48	15.8	500	0.7	99	304	3,072
85 and older												
Male	620	17.5	7,001	0.8	69	203	5.7	2,259	8.0	154	3,533	38,059
Disabled	517	17.4	5,845	0.8	69	120	4.0	1,358	0.8	189	2,965	32,131
64 or younger	485	17.4	5,479	0.8	70	106	3.8	1,208	0.8	197	2,795	30,289
65-74	26	18.1	299	0.7	53	6	4.2	66	1.0	140	144	1,567
75-84	5	22.7	60	0.8	67	7	31.8	82	8.0	110	22	252
	1	25.0	7	0.1	19	1	25.0	2	0.5	73	4	23
85 and older Other Eligibles	103	18.1	1,156	0.8	70	83	14.6	901	8.0	101	568	5,928
64 or younger	4	8.5	30	0.7	88	1	2.1	7	0.6	82	47	414
65-74	48	25.4	538	0.8	73	23	12.2	232	0.9	112	189	2,112
75-84	38	19.6	432	0.8	64	33	17.0	381	0.7	94	194	2,035
	13	9.4	156	0.8	74	26	18.8	281	0.7	102	138	1,367
85 and older Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 8,832 beneficiaries who were in nursing facilities for part of their enrollment and their 87,668 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

CALIFORNIA, 2004

	Number of	Percentage of							
	Beneficiaries with	Beneficiaries with at	Number of Part	Total Number Pa	art D Excluded			Part D Excluded Rx	
Beneficiary	at Least One Part	Least One Part D	D Excluded Rx	Part D	Rx \$ per	Total Part D	\$ per Part D \$	as a Percentage of	Total Number of
Characteristics	D Excluded Rx	Excluded Rx	per Beneficiary	Excluded Rx	Beneficiary	Excluded Rx \$	Excluded Rx	All Nondual Rx \$	Beneficiaries
All	1,005,622	17.8 %	0.6	3,297,966	\$14	\$78,883,516	\$24	5.0 %	5,642,718
Age									
5 and younger	272,180	27.9	0.7	724,807	19	18,890,415	26	43.2	974,623
6-14	110,361	14.3	0.4	288,215	19	14,398,599	50	13.5	772,516
15-20	94,078	10.5	0.2	204,410	7	6,254,391	31	6.5	898,823
21-44	330,388	13.4	0.3	843,001	7	16,062,424	19	3.1	2,458,046
45-64	158,953	34.9	2.2	1,015,613	43	19,779,539	19	2.8	455,109
65-74	26,197	49.6	2.7	144,243	41	2,164,571	15	2.9	52,866
75-84	11,196	47.4	2.7	63,785	45	1,055,261	17	3.1	23,622
85 and older	2,268	32.0	2.0	13,889	39	278,289	20	3.9	7,097
Unknown	1	6.3	0.2	3	2	27	9	0.0	16
Basis of Eligibility ^c									
Aged	34,360	46.2	2.4	182,250	38	2,833,566	16	3.0	74,413
Disabled	222,077	48.0	3.3	1,524,176	109	50,337,447	33	4.5	463,123
Adults	341,329	11.6	0.2	633,467	3	8,264,923	13	3.6	2,936,193
Children	405,693	18.8	0.4	950,390	8	17,337,458	18	12.8	2,163,000
Unknown	2,163	36.1	1.3	7,683	18	110,122	14	1.5	5,989
Gender									
Female	661,583	17.3	0.5	2,088,199	11	43,034,421	21	4.7	3,831,525
Male	344,038	19.0	0.7	1,209,762	20	35,849,047	30	5.4	1,811,185
Unknown	1	12.5	0.6	5	6	48	10	0.0	8
Race									
White	208,439	16.4	0.7	910,603	18	22,822,281	25	3.3	1,267,500
African American	80,076	17.1	0.7	313,839	18	8,670,913	28	4.5	468,867
Other/unknown	717,107	18.4	0.5	2,073,524	12	47,390,322	23	6.7	3,906,351
Use of Nursing									
Facilities ^d									
Entire year	3,817	55.4	5.5	37,953	120	825,201	22	2.3	6,886
Part year	6,283	71.1	5.4	47,565	154	1,363,747	29	3.5	8,832
None	995,522	17.7	0.6	3,212,448	14	76,694,568	24	5.1	5,627,000
Maintenance									
Assistance Status									
Cash	499,418	27.1	1.2	2,165,548	31	57,342,995	26	4.8	1,842,658
Medically needy	59,456	19.8	0.8	228,278	18	5,476,480	24	4.1	299,782
Poverty related	67,645	21.3	0.5	174,204	9	3,004,966	17	5.3	317,673
Other/unknown	379,103	11.9	0.2	729,936	4	13,059,075	18	6.5	3,182,605

Table ND11 Nondual Beneficiaries

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

CALIFORNIA, 2004

Beneficiary	Number Rx per	Rx \$ per		Barbiturate \$ per Benzodiazepine \$ per					
Characteristics	Benefit Month	Benefit Month	\$ per Rx	Benefit Month	Benefit Month	Benefit Months			
All	0.1	\$2	\$24	\$0	\$0	37,644,944			
Age									
5 and younger	0.2	4	26	0	0	4,524,994			
6-14	0.1	3	50	0	0	4,618,088			
15-20	0.0	1	31	0	0	6,074,316			
21-44	0.0	1	19	0	0	17,829,163			
45-64	0.3	5	19	0	1	3,807,105			
65-74	0.3	4	15	0	1	507,888			
75-84	0.3	5	17	0	0	226,339			
85 and older	0.2	5	20	0	1	57,024			
Unknown	0.1	1	9	0	0	27			
Basis of Eligibility ^c									
Aged	0.3	4	16	0	0	694,514			
Disabled	0.3	10	33	0	2	4,873,512			
Adults	0.0	0	13	0	0	20,604,975			
Children	0.1	2	18	0	0	11,412,232			
Unknown	0.1	2	14	0	1	59,711			
Gender									
Female	0.1	2	21	0	0	26,473,161			
Male	0.1	3	30	0	0	11,171,750			
Unknown	0.2	1	10	0	0	33			
Race									
White	0.1	2	25	0	1	9,642,029			
African American	0.1	3	28	0	0	3,149,575			
Other/unknown	0.1	2	23	0	0	24,853,340			
Use of Nursing									
Facilities ^d									
Entire year	0.5	11	22	1	5	74,877			
Part year	0.5	16	29	0	4	87,668			
None	0.1	2	24	0	0	37,482,399			
Maintenance Assistance Status									
Cash	0.2	5	26	0	1	12,434,242			
Medically needy	0.1	3	24	0	0	1,689,783			
Poverty related	0.1	2	17	0	0	1,639,436			
Other/unknown	0.0	1	18	0	0	21,881,483			

Table ND12 Nondual Beneficiaries

- a. Table ND.12 includes the beneficaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c} CALIFORNIA, 2004

	Rx \$ as a Percentage of All Part D										
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Excluded Rx \$	Total Number Rx.	\$ per Rx	Part D Excluded Rx				
All	1,236,887	\$64	\$78,883,516	100.0 %	3,297,966	\$24	100.0 %				
Anorexia or weight loss/gain	187	268	50,174	0.1	619	81	0.0				
Fertility drugs	10	126	1,256	0.0	22	57	0.0				
Drugs for cosmetic purposes	16	17	269	0.0	20	13	0.0				
Cough and cold medications	188,494	28	5,323,171	6.7	316,762	17	9.6				
Vitamins and minerals	74,670	40	2,950,458	3.7	167,656	18	5.1				
Non-prescription drugs	876,744	65	57,232,470	72.6	2,288,612	25	69.4				
Barbiturates	8,091	59	480,044	0.6	58,123	8	1.8				
Benzodiazepines	85,711	122	10,423,650	13.2	457,227	23	13.9				
Other Part D Excl Rx Drugs	2,964	817	2,422,024	3.1	8,925	271	0.3				

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

APPENDIX TABLE A.1
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, CALIFORNIA, 2004

Beneficiary			Number of Be	eneficiaries			Number of Benefit Months					
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	8,520,405	86,592	600,899	3,720,096	4,105,961	6,857	74,698,518	823,881	6,601,547	30,501,103	36,703,428	68,559
Age												
5 and younger	1,654,177	1	24,749	4	1,629,423	0	13,984,087	12	265,941	6	13,718,128	0
6-14	1,717,718	0	67,629	188	1,649,901	0	16,586,683	0	775,640	545	15,810,498	0
15-20	1,306,550	0	49,088	471,833	785,586	43	11,189,742	0	552,276	3,695,422	6,941,669	375
21-44	3,074,507	7	175,990	2,855,638	40,938	1,934	25,564,530	45	1,936,779	23,376,494	232,529	18,683
45-64	669,819	22	273,369	391,534	83	4,811	6,431,077	128	2,960,288	3,421,454	477	48,730
65-74	62,223	52,417	8,996	741	0	69	610,288	503,080	100,211	6,226	0	771
75-84	27,407	26,484	853	68	2	0	266,997	257,928	8,545	509	15	0
85 and older	7,986	7,661	225	90	10	0	65,082	62,688	1,867	447	80	0
Unknown	18	0	0	0	18	0	32	0	0	0	32	0
Gender												
Female	5,431,783	54,035	299,198	2,976,594	2,095,102	6,854	47,182,392	517,466	3,328,249	24,652,253	18,615,901	68,523
Male	3,088,612	32,557	301,701	743,502	2,010,849	3	27,516,086	306,415	3,273,298	5,848,850	18,087,487	36
Unknown	10	0	0	0	10	0	40	0	0	0	40	0
Race												
White	1,753,163	16,703	214,233	793,054	727,622	1,551	15,740,943	151,390	2,320,116	6,509,771	6,744,371	15,295
African American	860,117	2,817	111,811	328,044	417,050	395	8,230,773	23,937	1,235,231	2,817,781	4,149,951	3,873
Other/unknown	5,907,125	67,072	274,855	2,598,998	2,961,289	4,911	50,726,802	648,554	3,046,200	21,173,551	25,809,106	49,391
Use of Nursing Facilities ^c												
Entire year	7,095	1,383	5,635	34	39	4	77,098	14,596	61,834	216	410	42
Part year	9,280	1,548	7,247	333	118	34	95,655	15,413	75,899	2,955	1,035	353
None	8,504,030	83,661	588,017	3,719,729	4,105,804	6,819	74,525,765	793,872	6,463,814	30,497,932	36,701,983	68,164
Maintenance Assistance Status												
Cash	4,038,831	10,689	525,743	1,130,058	2,372,341	0	41,547,986	117,170	5,941,225	10,890,348	24,599,243	0
Medically needy	567,801	58,714	35,349	135,097	338,641	0	4,451,961	551,288	304,263	925,434	2,670,976	0
Poverty related	463,399	16,229	16,688	91,733	331,892	6,857	3,504,796	147,551	144,235	474,206	2,670,245	68,559
Other/unknown	3,450,374	960	23,119	2,363,208	1,063,087	0	25,193,775	7,872	211,824	18,211,115	6,762,964	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	4,499,194	72,003	437,337	2,593,052	1,390,873	5,929	33,714,274	682,284	4,737,742	19,450,678	8,784,118	59,452
FFS part year, with Rx claims	329,512	1,390	17,294	103,606	207,182	40	3,246,744	14,581	195,552	1,016,159	2,020,030	422
FFS part year, no Rx claims	814,012	1,020	8,492	239,535	564,945	20	7,620,929	9,452	89,081	2,199,581	5,322,611	204
MC all year, with Rx claims	52,203	224	26,006	11,896	14,061	16	593,357	2,458	305,712	133,507	151,508	172
MC all year, no Rx claims	2,825,484	11,955	111,770	772,007	1,928,900	852	29,523,214	115,106	1,273,460	7,701,178	20,425,161	8,309

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, CALIFORNIA, 2004

	Beneficiarie Benefit Months in Ce		Included in Cell K	of Table 1	Excluded from Cell	K of Table 1	
		umber of Benefit Months		umber of Benefit Months	Number of Number of Benefit Beneficiaries Months		
All	8,520,405	74,698,518	5,642,718	37,644,944	0	37,053,574	
Fee-for-service (FFS) all year	4,499,194	33,714,274	4,499,194	33,714,274	0	0	
FFS part year, with Rx claims	329,512	3,246,744	329,512	1,407,465	0	1,839,279	
FFS part year, with no Rx claims	814,012	7,620,929	814,012	2,523,205	0	5,097,724	
Managed care (MC) all year, with Rx claims	52,203	593,357	0	0	0	593,357	
MC all year, with no Rx claims	2,825,484	29,523,214	0	0	0	29,523,214	

Source: Data for this table are from the MAX 2004 file for California, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.